A J Oliveira-Maia

Champalimaud Research & Clinical Centre, Champalimaud Foundation, Av. Brasília, s/n, 1400-038 Lisboa, Portugal; NOVA Medical School, NMS, Universidade NOVA de Lisboa, Campo Mártires da Pátria, 130, 1169-056 Lisboa, Portugal.

2 papers in the library · 7 citations · publishing 2026

Papers

Ketamine-assisted psychotherapies for mental disorders: A historical overview and systematic review.

Clinical psychology review February 2, 2026 J K E Veraart, N Schimmers, J J Breeksema et al. 4 citations

Ketamine-assisted psychotherapy (KAP) combines psychotherapeutic interventions with the rapid-acting effects of ketamine to treat psychiatric disorders. This systematic review of 64 articles (72 studies) up to 2025 found only 11 were randomized controlled trials (RCTs), highlighting limited evidence. Therapeutic approaches varied, with most classified as 'other.' Results suggest transdiagnostic effectiveness for major depressive disorder, posttraumatic stress disorder, obsessive-compulsive disorder, substance use disorders, and eating disorders. Compared to psychotherapy alone, KAP enhanced treatment engagement, symptom reduction, and duration of response. However, only two studies randomized psychotherapy alongside ketamine, neither reporting added effects; one also randomized ketamine and found no significant interaction. This limited evidence does not support added benefit or synergy from combining psychotherapy with ketamine.

DOI: 10.1016/j.cpr.2026.102706 Full text Ketamine-assisted psychotherapy Psychiatric disorders Systematic review

Long-term treatment with esketamine nasal spray in patients with treatment resistant depression: Results from the ESCAPE-LTE study.

European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology June 1, 2026 A Reif, Yağcıoğlu Ae Anıl, I Bitter et al. 3 citations

A 2-year extension of a clinical trial followed 183 adults with treatment-resistant depression who had been using esketamine nasal spray alongside an antidepressant. Over 136 weeks, 96.7% reported side effects, but 98.3% of those occurring on dosing days resolved the same day, and only 3.3% stopped treatment due to side effects. Among patients who achieved remission during the earlier phase, 79.2% did not relapse or discontinue treatment throughout the extension; the overall relapse rate for those reaching remission across both studies was 6.9%. No new safety concerns emerged, and the safety profile matched that seen in shorter-term studies.

DOI: 10.1016/j.euroneuro.2026.112801 Full text Major depressive disorder Efficacy Esketamine nasal spray Long-term +3